This program is working to advance inhaled adeno-associated virus (AAV) delivery of the CFTR gene to the lungs. This would allow the lung cells to create normally functioning CFTR protein, regardless of an individual’s specific CFTR gene mutation.
Laboratory studies to develop and test this potential therapy are underway.
This program is sponsored by Spirovant Sciences (formerly Talee Bio) and partially funded by the Cystic Fibrosis Foundation.
Contact us about Spirovant Sciences >